InvestorsHub Logo
Followers 800
Posts 50862
Boards Moderated 2
Alias Born 12/12/2004

Re: crudeoil24 post# 8

Saturday, 02/13/2016 10:24:37 AM

Saturday, February 13, 2016 10:24:37 AM

Post# of 61
PFNX, HSP/(PFE) ink collaboration for Lucentis FoB:

http://finance.yahoo.com/news/pfenex-hospira-announce-collaboration-develop-141500337.html
Quote:
Pfenex Inc. and Hospira, Inc…today announced that the companies have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex's biosimilar candidate to Genentech's Lucentis (ranibizumab injection).

Under the terms of the collaboration, Pfenex will receive an upfront payment of $51 million once the collaboration receives antitrust approval, and, over the next five years and beyond, will be eligible to receive a combination of development and sales-based milestone payments up to an additional $291 million, and tiered double-digit royalty on net sales of the product.

Pfenex and Hospira will share the Phase 3 equivalence clinical trial costs, and Hospira will be responsible for manufacturing and commercializing the product worldwide.

DUKE BASKETBALL and NOTRE DAME FOOTBALL